Secchi J, Lecaque D, Dunn F W, Jouquey S, Auberval U D, Benzoni F, Sirugue O, Hamon G
Centre de Recherches Roussel UCLAF, Romainville, France.
J Cardiovasc Pharmacol. 1994;23 Suppl 4:S30-7.
The effects of a 3-month treatment period with the angiotensin-converting enzyme (ACE) inhibitors trandolapril (0.3 mg/kg/day, p.o.) and enalapril (10 mg/kg/day, p.o.) on hemodynamics, cardiac hypertrophy, and vascular structures were examined in old spontaneously hypertensive rats (SHRs) (24 months at the end of treatment) presenting with congestive heart failure. During the course of treatment, the mortality rate was lower in the two treated groups than in the control group. At the end of treatment, serum ACE activity was inhibited by 63 and 33% by trandolapril and enalapril, respectively, but the decrease in blood pressure they induced was not significant. The atrial natriuretic factor(ANF) plasma levels and cyclic GMP urine excretion were about 10-fold and 3-fold higher, respectively, in old SHRs than in old Wistar rats. These values were markedly decreased by both ACE inhibitors. The ventricular hypertrophy was greatly decreased by both compounds (-24% by trandolapril and -26% by enalapril). In the aorta, the media hypertrophy was significantly decreased and nuclear density increased to a similar extent by both ACE inhibitors. In the mesenteric artery, trandolapril treatment induced a complete regression of the media hypertrophy and a marked decrease in extracellular matrix surface. In addition, the collagen network appeared less dissociated in the treated animals. Similarly the nuclear density was increased and the surface of cell nuclei was decreased by trandolapril. Enalapril appeared much less potent on these parameters. These data demonstrate that treatment with trandolapril of aged SHRs presenting with heart failure results in an increase in survival of the animals and a marked regression of cardiac and vascular hypertrophy.(ABSTRACT TRUNCATED AT 250 WORDS)
在患有充血性心力衰竭的老年自发性高血压大鼠(SHRs)(治疗结束时24个月)中,研究了血管紧张素转换酶(ACE)抑制剂群多普利(0.3毫克/千克/天,口服)和依那普利(10毫克/千克/天,口服)为期3个月的治疗对血流动力学、心脏肥大和血管结构的影响。在治疗过程中,两个治疗组的死亡率均低于对照组。治疗结束时,群多普利和依那普利分别抑制血清ACE活性63%和33%,但它们引起的血压下降并不显著。老年SHRs的心房利钠因子(ANF)血浆水平和环磷酸鸟苷尿排泄量分别比老年Wistar大鼠高约10倍和3倍。两种ACE抑制剂均使这些值显著降低。两种化合物均使心室肥大显著降低(群多普利降低24%,依那普利降低26%)。在主动脉中,两种ACE抑制剂均使中膜肥大显著降低,核密度增加到相似程度。在肠系膜动脉中,群多普利治疗使中膜肥大完全消退,细胞外基质表面显著减少。此外,在治疗的动物中,胶原网络的解离似乎较少。同样,群多普利使核密度增加,细胞核表面减少。依那普利在这些参数上的作用似乎小得多。这些数据表明,用群多普利治疗患有心力衰竭的老年SHRs可提高动物的存活率,并使心脏和血管肥大显著消退。(摘要截断于250字)